Heart failure: implantable cardioverter defibrillator to prevent sudden death in patients with left ventricular systolic dysfunction
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 1999 Dec 16;341(25):1882-90 Randomized Controlled Trial
IN coronary disease, ventricular arrhythmia, sudden death The Use of
implantable cardioverter defibrillator
As Treatment, Chronic
Is better Than
antiarrhythmic drugs or no treatment
To reduce the risk of sudden death.
JAMA. 2004 Dec 15;292(23):2874-9 Meta-Analysis
IN heart failure, chronic, systolic, non-pharmacological treatment, nonischemic cardiomyopathy The Use of
implantable cardioverter defibrillator
As Treatment, Chronic
Is better Than
best medical treatment only
To reduce overall mortality: 30% RRR in time of follow-up not precised
N Engl J Med. 2005 Jan 20;352(3):225-237 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic, severe, non-pharmacological treatment, both ischemic and nonischemic cardiomyopathy The Use of
implantable cardioverter defibrillator
As Treatment, Chronic
Is better Than
amiodarone or placebo
To reduce mortality: 22% with defibrillator VS 29% with placebo at 46 months, absolute reduction 1,85% per year
N Engl J Med. 2005 Oct 6;353(14):1471-80 Cost-Effectiveness
IN heart failure, chronic, systolic, sudden death, non-pharmacological treatment The Use of
implantable cardioverter defibrillator
As Treatment, Chronic
Is better Than
conventional medical treatment, including antiarrhythmic drugs or not
To add between 1 and 3 quality-adjusted life-years (QALY) in 6 trials and no effective in 2 trials. Cost per QALY less than 100,000 dollars